Health ❯ Healthcare ❯ Medications

Diabetes

Ozempic Metformin GLP-1 Receptor Agonists GLP-1 Weight Management GLP-1 Medications GLP-1 Drugs Weight Loss Medications Weight Loss GLP-1 Agonists GLP-1 Therapy Rybelsus Sitagliptina/Metformina Normon Type 2 Diabetes Pediatric Diabetes Inhaled Insulin Mounjaro Clinical Trials Heart Disease Retatrutide

10 ARTICLES

last mo.

FDA Approves Mounjaro to Lower Heart‑Attack and Stroke Risk in High‑Risk Type 2 Diabetes

The agency cleared the label on Aug. 28, 2026 after Lilly’s head‑to‑head SURPASS‑CVOT showed a modest cardiovascular advantage over Trulicity, a result that broadens Mounjaro’s clinical and commercial role.

13 ARTICLES

2mo ago

Mounjaro Study Finds Lower Heart‑Attack Risk as UK Safety Reports Rise

5 ARTICLES

3mo ago

Study Finds Small Rise in Smell and Taste Diagnoses Among People on GLP‑1 Diabetes Drugs

8 ARTICLES

6mo ago

GLP-1 Agonists Tied to Higher Risk of Macular Degeneration and Rare Optic Neuropathy

Diabetes

FDA Approves Mounjaro to Lower Heart‑Attack and Stroke Risk in High‑Risk Type 2 Diabetes

Mounjaro Study Finds Lower Heart‑Attack Risk as UK Safety Reports Rise

Study Finds Small Rise in Smell and Taste Diagnoses Among People on GLP‑1 Diabetes Drugs

Heart Risks Rebound After GLP-1 Breaks, New Data Show Continuous Use Is Safest

Randomized Trial Finds Metformin Dulls Key Gains From Exercise

EMA Approves Cardiovascular Indication for Novo Nordisk’s Rybelsus

Rosie O’Donnell Says She’s Shocked to Fit Size 12, Calls Mounjaro ‘Life Saver’

GLP-1 Agonists Tied to Higher Risk of Macular Degeneration and Rare Optic Neuropathy